Two new analyses from HELIOS-B answer important questions, but some uncertainties remain, says Julie Rosenthal.

Background Significant secondary mitral regurgitation (SMR) is known to be associated with worse prognosis. However, data ...

Alnylam Pharmaceuticals has agreed to drop its 2023 patent lawsuit against Moderna in a Delaware court following a judge's ...

Alnylam backed down after judge’s patent interpretation favoured Moderna | Case is part of a spate of infringement lawsuits ...

Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined.

With the business potentially at an important milestone, we thought we'd take a closer look at Alnylam Pharmaceuticals, ...

BridgeBio Pharma BBIO) stock received a Perform rating from Oppenheimer on market challenges to its late-stage assets acoramidis and infigratinib. Read more here.

Alnylam Pharmaceuticals admitted defeat, for now, in a lawsuit in Delaware federal court that accused Moderna's blockbuster ...

Alnylam's Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.

In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), ...

BioMarin is adding kindling to the R&D fire, striking a match with CAMP4 Therapeutics for rights to select two targets ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Alnylam Pharmaceuticals (ALNY) is a stock that can certainly grab the attention of ...